Active Ingredient(s): Nusinersen
FDA Approved: * December 23, 2016
Pharm Company: * BIOGEN
Category: Neurological Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Spinraza Overview

Nusinersen,[3] marketed as Spinraza,[1] is a medication used in treating spinal muscular atrophy (SMA), a rare neuromuscular disorder.[4][1] In December 2016, it became the first approved drug used in treating this disorder. Since the condition it treats is so rare, Nusinersen has so-called “orphan drug” designation in the United States and the European Union.[5] Contents 1 Medical uses 2 Side effect...

Read more Spinraza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Nusinersen

Recent Spinraza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 2.4mg/ml
  • Solution: 12mg/5ml (2.4mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Spinraza: (1 result)

Sorted by National Drug Code
  • 64406-058 Spinraza 2.4 mg/ml Intrathecal Injection, Solution by Biogen

Other drugs which contain Nusinersen or a similar ingredient: (1 result)